Contemporary Molecular Markers for Predicting Systemic Treatment Response in Urothelial Bladder Cancer: A Narrative Review

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Sep 14

PMID 39272913

Authors

George Dimitrov

Radoslav Mangaldzhiev

Chavdar Slavov

Elenko Popov

Affiliations

Soon will be listed here.

Abstract

The search for dependable molecular biomarkers to enhance routine clinical practice is a compelling challenge across all oncology fields. Urothelial bladder carcinoma, known for its significant heterogeneity, presents difficulties in predicting responses to systemic therapies and outcomes post-radical cystectomy. Recent advancements in molecular cancer biology offer promising avenues to understand the disease's biology and identify emerging predictive biomarkers. Stratifying patients based on their recurrence risk post-curative treatment or predicting the efficacy of conventional and targeted therapies could catalyze personalized treatment selection and disease surveillance. Despite progress, reliable molecular biomarkers to forecast responses to systemic agents, in neoadjuvant, adjuvant, or palliative treatment settings, are still lacking, underscoring an urgent unmet need. This review aims to delve into the utilization of current and emerging molecular signatures across various stages of urothelial bladder carcinoma to predict responses to systemic therapy.

References

Chou J, Trepka K, Sjostrom M, Egusa E, Chu C, Zhu J . TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. Eur Urol Oncol. 2022; 5(6):714-718. PMC: 10262920. DOI: 10.1016/j.euo.2021.11.005. View

Babjuk M, Burger M, Capoun O, Cohen D, Comperat E, Dominguez Escrig J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2021; 81(1):75-94. DOI: 10.1016/j.eururo.2021.08.010. View

Lv L, Li Y, Deng H, Zhang C, Pu Y, Qian L . MiR-193a-3p promotes the multi-chemoresistance of bladder cancer by targeting the HOXC9 gene. Cancer Lett. 2014; 357(1):105-113. DOI: 10.1016/j.canlet.2014.11.002. View

Hensley P, Kyprianou N, Purdom M, He D, DiCarlo V, Wang C . Predictive value of phenotypic signatures of bladder cancer response to cisplatin-based neoadjuvant chemotherapy. Urol Oncol. 2019; 37(9):572.e1-572.e11. PMC: 9186422. DOI: 10.1016/j.urolonc.2019.06.020. View

Teo M, Mota J, Whiting K, Li H, Funt S, Lee C . Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. Eur Urol. 2020; 78(6):907-915. PMC: 8215618. DOI: 10.1016/j.eururo.2020.07.018. View

Manzano R, Catalan-Latorre A, Brugarolas A . RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer. BMC Cancer. 2021; 21(1):432. PMC: 8056512. DOI: 10.1186/s12885-021-08078-y. View

Ligthart S, Coumans F, Attard G, Mulick Cassidy A, de Bono J, Terstappen L . Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival. PLoS One. 2011; 6(11):e27419. PMC: 3210171. DOI: 10.1371/journal.pone.0027419. View

Zhang X, Zhang Y, Liu X, Fang A, Li P, Li Z . MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin. PLoS One. 2015; 10(11):e0143441. PMC: 4657877. DOI: 10.1371/journal.pone.0143441. View

Sanguedolce F, Zanelli M, Palicelli A, Ascani S, Zizzo M, Cocco G . Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression. Int J Mol Sci. 2022; 23(14). PMC: 9319819. DOI: 10.3390/ijms23147819. View

10.

Lindskrog S, Prip F, Lamy P, Taber A, Groeneveld C, Birkenkamp-Demtroder K . An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun. 2021; 12(1):2301. PMC: 8052448. DOI: 10.1038/s41467-021-22465-w. View

11.

Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Luciano R . Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol. 2018; 36(34):3353-3360. DOI: 10.1200/JCO.18.01148. View

12.

Claps F, Mir M, Zargar H . Molecular markers of systemic therapy response in urothelial carcinoma. Asian J Urol. 2021; 8(4):376-390. PMC: 8566362. DOI: 10.1016/j.ajur.2021.05.001. View

13.

Laukhtina E, Hassler M, Pradere B, Yanagisawa T, Quhal F, Rajwa P . Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma. Eur Urol Focus. 2022; 8(6):1683-1686. DOI: 10.1016/j.euf.2022.04.017. View

14.

Choueiri T, Jacobus S, Bellmunt J, Qu A, Appleman L, Tretter C . Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014; 32(18):1889-94. PMC: 7057274. DOI: 10.1200/JCO.2013.52.4785. View

15.

Oudard S, Culine S, Vano Y, Goldwasser F, Theodore C, Nguyen T . Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. Eur J Cancer. 2014; 51(1):45-54. DOI: 10.1016/j.ejca.2014.10.009. View

16.

Lerner S, McConkey D, Hoadley K, Chan K, Kim W, Radvanyi F . Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting. Bladder Cancer. 2016; 2(1):37-47. PMC: 4927916. DOI: 10.3233/BLC-150037. View

17.

Liu J, Wang H, Wang Y, Li Z, Pan Y, Liu Q . Repression of the miR-93-enhanced sensitivity of bladder carcinoma to chemotherapy involves the regulation of LASS2. Onco Targets Ther. 2016; 9:1813-22. PMC: 4821379. DOI: 10.2147/OTT.S97399. View

18.

Vandekerkhove G, Todenhofer T, Annala M, Struss W, Wong A, Beja K . Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. Clin Cancer Res. 2017; 23(21):6487-6497. DOI: 10.1158/1078-0432.CCR-17-1140. View

19.

. Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials. Eur Urol. 2021; 81(1):50-61. PMC: 8708165. DOI: 10.1016/j.eururo.2021.09.028. View

20.

Khetrapal P, Lee M, Tan W, Dong L, de Winter P, Feber A . The role of circulating tumour cells and nucleic acids in blood for the detection of bladder cancer: A systematic review. Cancer Treat Rev. 2018; 66:56-63. DOI: 10.1016/j.ctrv.2018.03.007. View